Autopsy report · NCT04809623

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

“Sponsor decision to terminate study.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 1 year 2 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Gilead Sciences

Sponsor type

Industry

Conditions

Cutaneous Lupus Erythematosus

Interventions

Edecesertib; Placebo; Standard of Care

Participants

3

Sites

5

Countries

United States

Trials that died the same way

• Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers
  “Sponsor decision to terminate the study” (97% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (94% match in meaning)
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (93% match in meaning)
• The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
  “Business decision by sponsor to terminate the study” (93% match in meaning)
• Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
  “Study termination by the Sponsor” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.